These drugs are second‐generation inhibitors of the BCR‐ABL tyrosine kinase and approved for treatment of chronic myelogenous leukemia (CML; Molica et al, 2017). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.